The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1
Abstract
BACKGROUND: Sirolimus is an immunosuppressive drug recently developed for organ transplantation. Its mechanism of action, independent of calcineurin, is different from that of cyclosporine and tacrolimus, two calcineurin inhibitors (CIs). Because the toxicity of CIs is partly the result of calcineurin blockade, sirolimus exhibits a different toxicity profile. In this study, we evaluated the profile, frequency, and severity of cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. PATIENTS AND METHODS: A systematic and in-depth evaluation of skin, mucous membranes, nails, and hair was performed in 80 renal transplant recipients receiving sirolimus-based therapy. The mean duration of the graft was 6 years and of sirolimus treatment was 18 months. Mycophenolate mofetil and steroids were combined with sirolimus for 74 patients. Sirolimus was used as first immunosuppressive therapy for 36 patients, and 44 patients were switched from CIs to sirolimus. RESULTS: Seventy-nine patients (99%) experienced cutaneous adverse events. Twenty patients (25%) demonstrated serious adverse events, and six patients (7%) stopped sirolimus during the 3 months after the study because of cutaneous events. The most frequent of these were pilosebaceous apparatus involvement, including acne-like eruptions (46%), scalp folliculitis (26%), and hidradenitis suppurativa (12%); edematous complaints, including chronic edemas (55%) and angioedema (15%); mucous membrane disorders, including aphthous ulceration (60%), epistaxis (60%), chronic gingivitis (20%), and chronic fissure of the lips (11%); and last, nail disorders including chronic onychopathy (74%) and periungual infections (16%). CONCLUSIONS: Skin disorders are frequent in renal transplant recipients receiving sirolimus as a long-term therapy. Despite the usually mild nature of skin events, they are often the reason for stopping sirolimus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Israili, Z. H., & Hall, W. D. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-3-234 · Cited by 910
Drug-Induced Angioedema without Urticaria: Incidence, Prevention and Management
Agostoni, A., & Cicardi, M. (2001) · Drug Safety · doi:10.2165/00002018-200124080-00004 · Cited by 154 · cited 1×
“They may develop at any time from a few hours to many years after ACEI introduction (35, 36).”
Cited by
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64099 · Cited by 531
Revuz, J. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03356.x · Cited by 336
Skin Cancer in Organ Transplant Recipients—Where Do We Stand Today?
Ulrich, C., Kanitakis, J., Stockfleth, E., & Euvrard, S. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02386.x · Cited by 278
Adverse events associated with mTOR inhibitors
Pallet, N., & Legendre, C. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752814 · Cited by 198
Arriola Apelo, S. I., Neuman, J. C., Baar, E. L., Syed, F. A., Cummings, N. E., Brar, H. K., Pumper, C. P., Kimple, M. E., & Lamming, D. W. (2016) · Aging Cell · doi:10.1111/acel.12405 · Cited by 182
“However, in addition to a reported increase in viral and fungal infections in humans taking rapamycin (Mahe et al., 2005), even short-term low-dose rapamycin decreases defense against bacterial and viral pathogens inmice (Goldberget al., 2014).”
Background
Metadata
- Authors
- Mah??, E., Morelon, E., Lechaton, S., Sang, K.-H. L. Q., Mansouri, R., Ducasse, M.-F., Mamzer-Bruneel, M.-F., de Prost, Y., Kreis, H., & Bodemer, C.
- Venue
- Transplantation
- Published
- 2005-02
- Volume
- 79
- Issue
- 4
- Pages
- 476-482
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1999510271
- Cited by
- 228
- References
- 2
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1. https://app.cochat.ai/papers/10.1097/01.tp.0000151630.25127.3a
- The paper
- Mah??, E., Morelon, E., Lechaton, S., Sang, K.-H. L. Q., Mansouri, R., Ducasse, M.-F., Mamzer-Bruneel, M.-F., de Prost, Y., Kreis, H., & Bodemer, C. (2005). Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1. Transplantation. https://doi.org/10.1097/01.tp.0000151630.25127.3a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.